ACUTE MYELOID LEUKEMIA REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune cell therapy takes on tough childhood leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 17, 2026 01:49 UTC
-
New hope for tough leukemias: experimental drug APL-4098 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 01:47 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:46 UTC
-
New combo therapy offers hope for young leukemia patients who've relapsed
Disease control Recruiting nowThis early-stage study tests whether adding the drug venetoclax to two other medications (5-azacitidine and vorinostat) followed by standard chemotherapy can improve treatment response in children and young adults with acute myeloid leukemia that has come back or not responded to…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for tough leukemia: daily drug trial opens
Disease control Recruiting nowThis study tests a daily intravenous drug called AB8939 in adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The main goal is to find a safe dose and see if the drug can shrink or control the cancer. About 78 participants will take p…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for tough blood cancers: ARD103 trial opens
Disease control Recruiting nowThis study tests a new drug called ARD103 in about 49 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or not improved with standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. Participants will rec…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Immune cell booster shot targets tough leukemia
Disease control Recruiting nowThis early-phase study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment combines specially trained natural killer (NK) cells with a drug called atezolizumab, which may help the immune system …
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for tough leukemia: tiny fat bubbles deliver targeted therapy
Disease control Recruiting nowThis early-phase study tests a new drug called C6 ceramide NanoLiposome (CNL) in 15 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also watch…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
4,000 leukemia patients tracked to see what treatments work best in real life
Knowledge-focused Recruiting nowThis study will follow 4,000 adults whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments patients receive and how long they live, without giving any new medicine themselves. The goal is to learn what re…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:58 UTC